Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 6/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353557 | 1.00 | RAD52 (0.44) | RAD52PIK3CAAKT1PRKDCPIK3CD | |
| SCHEMBL25626249 | 0.80 | PIK3CD (0.44) | RAD52PIK3CAAKT1PRKDCPIK3CD | |
| SCHEMBL30353552 | 0.80 | PIK3CD (0.44) | RAD52PIK3CAAKT1PRKDCPIK3CD | |
| SCHEMBL25626205 | 0.78 | L3MBTL1 (0.50) | PIK3CA | |
| SCHEMBL30353514 | 0.77 | MTOR (0.47) | RAD52PIK3CAAKT1PIK3CDPIK3CG | |
| SCHEMBL25626250 | 0.77 | MTOR (0.47) | RAD52PIK3CAAKT1PIK3CDPIK3CG | |
| SCHEMBL4121103 | 0.70 | PIK3CA (0.53) | RAD52PIK3CAPRKDCPIK3CDPIK3CB | |
| SCHEMBL25626203 | 0.70 | PRKDC (0.41) | RAD52PIK3CAPRKDCPIK3CDPIK3CB | |
| SCHEMBL25220780 | 0.69 | PIK3CA (0.47) | RAD52PIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL30447441 | 0.69 | PIK3CA (0.47) | RAD52PIK3CAPIK3CBPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023107623-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | NLN, GRIN2C, BCHE | RAD52 1841/4885PIK3CA 4620/4885AKT1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.